A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Multiple Myeloma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 395 (final count)
- Started
- Nov 6, 2018
- Main results expected
- May 7, 2024
- Fully finished
- Apr 21, 2026
- Results posted
- Apr 8, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Primary Analysis: Overall Minimal Residual Disease (MRD) Negative Rate
Measured over: From randomization (Day 1) up to 27.9 months
Final Progression-Free Survival (PFS) Analysis : Overall Minimal Residual Disease (MRD) Negative Rate
Measured over: From randomization (Day 1) up to 64.8 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03652064 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC